BIOMAT Database Logo BIOMAT Database Logo

Ovulation inhibition by a new low-dose progestagen. 1977

L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko

UI MeSH Term Description Entries
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D010060 Ovulation The discharge of an OVUM from a rupturing follicle in the OVARY. Ovulations
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D005640 Follicle Stimulating Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity. FSH (Follicle Stimulating Hormone),Follicle-Stimulating Hormone,Follitropin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D045167 Progesterone Congeners Steroidal compounds related to PROGESTERONE, the major mammalian progestational hormone. Progesterone congeners include important progesterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with progestational activities. Synthetic Progestin,Progestagens, Synthetic,Progestational Hormone Analogs,Progestational Hormone Analogues,Progestational Hormones, Synthetic,Progestin Analogs,Progestin Analogues,Progestins, Synthetic,Progestogens, Synthetic,Synthetic Progestational Hormones,Synthetic Progestins,Progestin, Synthetic,Synthetic Progestagens,Synthetic Progestogens

Related Publications

L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Inhibition of ovulation by a new low-dose monophasic contraceptive containing gestodene.
September 1989, International journal of fertility,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Long-lasting ovulation inhibition with a new injectable progestagen ORG-2154.
June 1982, Contraception,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Inhibition of ovulation by low-dose mifepristone (RU 486).
August 1992, Human reproduction (Oxford, England),
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
A clinical trial of a new totally synthetic low dose progestagen.
February 1969, Journal of reproduction and fertility,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Inhibition of ovulation by low-dose monophasic contraceptive containing gestodene.
October 1990, American journal of obstetrics and gynecology,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Clinical evaluation of a new low dose progestagen-only contraceptive containing cingestol.
January 1974, International journal of fertility,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Continuous low-dose progestagen oral contraceptives.
February 1974, Drug and therapeutics bulletin,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Continuous low dose progestagen for contraception.
January 1968, IPPF medical bulletin,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
[Oral contraception with low-dose progestagen].
April 1989, Medizinische Monatsschrift fur Pharmazeuten,
L Viinikka, and E Hirvonen, and O Ylikorkala, and S Nummi, and P Virkkunen, and T Ranta, and U Alapiessa, and R Vihko
Continuous low-dose progestagen oral contraceptives.
January 1979, Drug and therapeutics bulletin,
Copied contents to your clipboard!